UAE approves Sinopharm’s protein-based vaccine
The vaccine will be produced and distributed by a joint venture between the UAE's Group 42 and China National Biotec Group (CNBG), a unit of China National Pharmaceutical Group (Sinopharm)
The United Arab Emirates (UAE) has approved emergency use of Sinopharm’s protein-based COVID-19 vaccine and it will be available to the public as a booster dose starting January 2022, the health ministry said.
The vaccine will be produced and distributed by a joint venture between the UAE’s Group 42 and China National Biotec Group (CNBG), a unit of China National Pharmaceutical Group (Sinopharm), the ministry said in a statement on state media yesterday.
The approval came following a UAE-based study that included individuals who were previously vaccinated with two doses of Sinopharm CNBG’s inactivated vaccine, the ministry added.
Edits by EP News Bureau
- Advertisement -